ALS 2016

The goal of the Canada: ALS 2016 program is to provide targeted support for outstanding translational research that accelerates the development of safe and effective therapies for amyotrophic lateral sclerosis.

ALS 2016 Awardees


Identification and validation of small molecules targeting the amyloidogenic core of TDP-43 as therapeutics for ALS/FTLD

Grantees: Dr. Janice Robertson , Dr. Donald Weaver , Dr. Christopher Barden , Dr. Avi Chakrabbarty

Project description Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease that affects motor neurons of the brain and spinal cord causing paralysis and death within 2-5 years from...

More


A Novel Diagnostic Test for Early Detection of Amyotrophic Lateral Sclerosis

Grantees: Dr. Yingfu Li , Dr. Bruno Salena , Dr. John Turnbull

Project description Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by the gradual loss of motor neurone in the brain and spinal cord, resulting in progressive weakness...

More